OC
WGS icon

Oppenheimer & Co’s GeneDx Holdings WGS Stock Holding History

Oppenheimer & Co’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
+7,301
New +$666K 0.01% 1212
2025
Q4 		– Sell
-2,201
Closed -$237K – 1751
2025
Q3 		$237K Buy
+2,201
New +$240K ﹤0.01% 1479

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oppenheimer & Co's WGS Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in GeneDx Holdings (WGS) in Q1 2026: 7,301 shares worth $469K. The stake represents 0.01% of the portfolio and ranks #1212 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in WGS as recently as Q3 2025.

Oppenheimer & Co first reported a position in WGS in Q3 2025 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Oppenheimer & Co held 7,301 shares of GeneDx Holdings worth $469K as of Q1 2026.
  • GeneDx Holdings was a new Oppenheimer & Co position in Q1 2026.
  • GeneDx Holdings made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1212 holding.
  • Oppenheimer & Co first reported a position in GeneDx Holdings in Q3 2025 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.